Project Name: Imperial breast cancer service transformation
Project Summary:
This CWP will fund, for a period of 24 months, one 0.6FTE (band 8a) Allied Health Professional (AHP) and one General Practitioner (GP) post to lead a service transformation programme to develop a comprehensive endocrine support service for the 1500-2000 patients currently in the open access follow up cohort. The GP and AHP will have clinical experience in breast cancer plus leadership and transformation skills or experience, the CWP will also fund one FTE Cancer care coordinator role (band 4).
Planned Milestones:
- Kick off meeting
- Confirmation from the CW Partner of the employment of GP, AHP and cancer care coordinator; on-boarding and familiarization.
- Complete baseline report for all datapoints outlined in Project outcome measures
- Launch of new endocrine clinic 3-month pilot; CWP to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria”.
- Project outcome measure review meeting of endocrine clinic, post development phase; CWP to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria”.
- Project outcome measure review meeting of endocrine clinic, post development phase; CWP to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria”.
- Project outcome measure review meeting of endocrine clinic, post development phase; CWP to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria”.
- Project outcome measure review meeting of endocrine clinic, post development phase; CWP to monitor and collect data, provide anonymised report containing such data to Novartis to assess against milestone, as applicable, as per the measurement criteria outlined in the “Project Outcomes and Measurement Criteria”.
- Submit business case to support future funding of co-ordinator role by the CW partner to continue with the service.
- Submit final CWP report to Novartis. Completion of the outcomes summary in collaboration with Novartis, for publishing in line with the ABPI guidelines.
Expected Benefits:
Anticipated benefits for patients:
- Equitable, timely access to endocrine therapies (CDK4/6i) by designing and implementing new endocrine clinics for patients with early breast cancer.
- Reduced risk of recurrence of breast cancer through optimising treatment and educating/informing patients to raise awareness
- Improved integrated care services (patient-centred care) and provide care closer to home, through mapping existing services and engaging patients, caregivers and community groups, design new pathways for diagnostics, health information and services which are accessible to local communities.
- Improved access to health information for underserved populations through inclusive media.
Anticipated benefits for the CWP:
- Improved integrated care services (patient-centred care) and provide care closer to home. Through mapping existing services and engaging patients, caregivers and community groups, design new pathways for diagnostics, health information and services which are accessible to local communities.
- Improved patient experience by designing a service which is designed to fit their needs, utilising PREMS.
- Improved access to health information for underserved populations through inclusive media.
- Improved workforce satisfaction by creating efficiencies in workflows and reducing the admin burden through the addition of a coordinator role.
Anticipated benefits to Novartis:
- Better understanding of overall HCP and patient needs
- Optimal use of medicines in line with local/national guidance (including Novartis medicines) in appropriate patients.
- Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisations
Start Date & Duration: July 2025 duration 24 months.
FA-11473080 | July 2025